1. P-glycoprotein (P-gp) is a transmembrane protein involved in ATP-dependent efflux of
various structurally unrelated anticancer drugs. Its overexpression in cancer cells decreases …

Multidrug resistance (MDR) of cancer tissue is a phenomenon in which cancer cells exhibit
reduced sensitivity to a large group of unrelated drugs with different mechanisms of …

Drug resistance, be it intrinsic or acquired, is a major problem in cancer chemotherapy. In
vitro, one well characterised form of resistance against many different cytotoxic drugs is …

P-glycoprotein (P-gp) is the plasma membrane transport pump responsible for efflux of
chemotherapeutic agents from cells and is one of the systems that secures multidrug …

Chemotherapy is one of the prevailing methods used to treat malignant tumours, but the
outcome and prognosis of tumour patients are not optimistic. Cancer cells gradually …

P-glycoprotein is one of the most well-studied drug transporters, significant for its role in
cancer multiple drug resistance. However, using P-gp inhibitors with the aim of enhancing …

The overexpression of P-glycoprotein (P-gp) causes resistance to chemotherapy in many
tumor types. Here, we report intercellular transfer of functional P-gp from P-gp-positive to P …

Multidrug resistance represents a major obstacle to successful chemotherapy of metastatic
disease. Elevated levels in cancer cells if the product of the multidrug resistance gene, P …

Multidrug resistance represents a major obstacle in the successful therapy of neoplastic
diseases. Studies have demonstrated that this form of drug resistance occurs both in …

Although the phenomenon of simultaneous resistance to multiple cytotoxic drugs (multidrug
resistance) in cancer cells has been discussed for more than two decades, and the human …